Johnson & Johnson Runs Into Vaccine Supply Issues In Europe Threatening Second-quarter Delivery Pledge Reuters

Johnson & Johnson execs have assured investors and officials that the company is "comfortable" hitting its vaccine delivery targets. But with its U.S. rollout underway, the pharma giant has run into some supply problems in Europe, Reuters reports. J&J’s shot isn’t yet authorized in Europe, but the company has been gearing up to supply a promised 55 million doses during the second quarter—and now it's hitting some snags, an official involved in supply talks told the news service. The shot is expected to win an EU authorization in the coming days, Reuters reports, and vaccinations in the bloc could start next month. The company notified European officials last week that it was “under stress” to meet the goal because of shortfalls in the supply of production materials, the source told Reuters. J&J might still be able to meet its target, the official added Two documents—a German health ministry internal document and a schedule published by Italian officials—confirm that J&J committed to delivering 55 million doses in the second quarter, according to Reuters. The news comes after execs assured analysts during the company’s first-quarter conference call that J&J was “comfortable” meeting all its delivery targets for the year. Still, CFO Joe Wolk acknowledged on the call there could be some “fluidity” to delivery timelines. J&J has pledged 200 million doses to Europe for 2021.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!